Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
13.08. | Enliven Therapeutics, Inc Q2 Loss Climbs | 1 | RTTNews | ||
13.08. | Enliven Therapeutics GAAP EPS of -$0.49 beats by $0.04 | 1 | Seeking Alpha | ||
ENLIVEN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
13.08. | Enliven Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
13.08. | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update | 214 | PR Newswire | Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks... ► Artikel lesen | |
25.06. | Enliven Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
20.06. | TD Cowen bekräftigt Kaufempfehlung für Enliven Therapeutics-Aktie | 1 | Investing.com Deutsch | ||
20.06. | TD Cowen reiterates buy rating on Enliven Therapeutics stock | 1 | Investing.com | ||
16.06. | Goldman Sachs initiates Enliven Therapeutics stock with Buy rating | 1 | Investing.com | ||
13.06. | Enliven Therapeutics prices $200 million public offering | 1 | Investing.com | ||
13.06. | Enliven Therapeutics stock falls after pricing capital raise of $200M via securities offering | 1 | Seeking Alpha | ||
13.06. | Enliven Therapeutics announces $200 million public offering | 5 | Investing.com | ||
13.06. | Enliven Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
13.06. | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress | 335 | PR Newswire | Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent... ► Artikel lesen | |
30.05. | Mizuho erhöht Kursziel für Enliven Therapeutics-Aktie auf 41 US-Dollar | 1 | Investing.com Deutsch | ||
16.05. | BTIG raises Enliven Therapeutics stock target to $45 | 1 | Investing.com | ||
15.05. | Enliven Therapeutics GAAP EPS of -$0.57 beats by $0.01 | 1 | Seeking Alpha | ||
15.05. | Enliven Therapeutics stock target raised to $40 at H.C. Wainwright | 1 | Investing.com | ||
14.05. | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update | 458 | PR Newswire | Updated data from the Phase 1 ENABLE clinical trial of ELVN-001 in CML to be presented at the EHA 2025 Congress in June
EHA abstract reported cumulative MMR rate... ► Artikel lesen | |
14.05. | Enliven reports positive Phase 1 trial data for ELVN-001 in CML | 1 | Investing.com | ||
14.05. | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress | 483 | PR Newswire | Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
VALNEVA | 4,220 | -2,45 % | Valneva-Aktie im freien Fall - droht zum Wochenstart der nächste Kurssturz? | ||
BIOFRONTERA | 2,840 | +5,97 % | PTA-News: Biofrontera AG: Biofrontera berichtet über die Ergebnisse des ersten Halbjahres 2025 | DJ PTA-News: Biofrontera AG: Biofrontera berichtet über die Ergebnisse des ersten Halbjahres 2025
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: Biofrontera berichtet über... ► Artikel lesen | |
CRISPR THERAPEUTICS | 60,00 | +0,84 % | CRISPR THERAPEUTICS AG verharrt - jetzt wird's brenzlig! | ||
AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
DENALI THERAPEUTICS | 14,180 | -0,67 % | Denali Therapeutics Inc.: Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome) | SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that the U.S. Food and Drug Administration (FDA) has extended its review timeline... ► Artikel lesen | |
FATE THERAPEUTICS | 1,280 | +1,23 % | FATE THERAPEUTICS INC - 8-K, Current Report | ||
AGIOS | 36,000 | -1,10 % | Avanzanite Bioscience B.V.: Avanzanite-Bioscience-Partner Agios gibt positive CHMP-Stellungnahme für PYRUKYND (Mitapivat) bei erwachsenen Patienten mit Thalassämie bekannt | Avanzanite ging im Juni 2025 eine exklusive Partnerschaft mit Agios zur Steuerung der Kommerzialisierung von PYRUKYND in Europa ein
Die Europäische Kommission wird die CHMP-Stellungnahme... ► Artikel lesen | |
CELLECTIS | 3,255 | -4,96 % | Cellectis: Barclays hebt Kursziel nach Fortschritten bei Krebstherapie deutlich an | ||
VOYAGER THERAPEUTICS | 4,316 | +1,65 % | Voyager Therapeutics, Inc.: Voyager Reports Second Quarter 2025 Financial and Operating Results | - Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs - - APOE program added to pipeline; fourth asset in industry-leading Alzheimer's disease franchise... ► Artikel lesen | |
UNIQURE | 50,42 | +1,53 % | Small-Cap-Biotech und UniQure: Die Gewinner der nächsten Biotech-Rallye! | Der Biotechnologiesektor boomt, mit Small-Cap-Biotech als Treiber. Zinssenkungen und verstärkte M&A-Aktivitäten bieten weiteres Potenzial, während Unternehmen wie UniQure mit bahnbrechenden Therapien... ► Artikel lesen | |
ENZO BIOCHEM | 0,388 | 0,00 % | Battery Ventures Completes Take-Private of Enzo Biochem | Apter joins as CEO to support the next stage of growth for the life-science reagents platform
BOSTON--(BUSINESS WIRE)--Battery Ventures, a global, technology-focused investment firm, announced the... ► Artikel lesen | |
TECTONIC THERAPEUTIC | 17,280 | -2,10 % | Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025 | Data confirmed TX45's tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved... ► Artikel lesen | |
SCILEX | 12,790 | -3,87 % | Scilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals, Inc. Warrant Repurchase | PALO ALTO, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and... ► Artikel lesen | |
ALLOGENE THERAPEUTICS | 1,240 | -2,36 % | Allogene licensor Cellectis faces patent lawsuit in the U.S. | ||
NUVATION BIO | 3,405 | -6,07 % | Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer | Sustained durability of responses demonstrated in both TRUST-I and TRUST-II with additional follow-up time TKI-naïve patients in TRUST-I achieved a median progression-free survival of 44.6 months... ► Artikel lesen |